Bioventix Plc Posting of Annual Report and Notice of AGM

 
TIDMBVXP 
 
8 November 2022 
 
 
                                 Bioventix plc 
                        ("Bioventix" or the "Company") 
 
                  Posting of Annual Report and Notice of AGM 
 
Bioventix plc (AIM: BVXP), a UK company specialising in the development and 
commercial supply of high-affinity monoclonal antibodies for applications in 
clinical diagnostics, announces that it has today posted its Annual Report for 
the year ended 30 June 2022 together with a Notice of Annual General Meeting 
("AGM") and Form of Proxy to shareholders that have elected to receive 
documentation in hard copy format. Both documents will also be available from 
the Company's website at www.bioventix.com under the Investors section. 
 
The Company's AGM will be held at Farnham Castle, Farnham, Surrey, GU9 0AG on 
Thursday 8 December 2022 at 2.00pm. 
 
For further information please contact: 
 
Bioventix plc                                      Tel: 01252 728 001 
Peter Harrison                  Chief Executive 
                                Officer 
 
finnCap Ltd                                        Tel: 020 7220 0500 
Geoff Nash/Simon Hicks          Corporate Finance 
Alice Lane                      ECM 
 
About Bioventix plc: 
 
Bioventix (www.bioventix.com) specialises in the development and commercial 
supply of high-affinity monoclonal antibodies with a primary focus on their 
application in clinical diagnostics, such as in automated immunoassays used in 
blood testing. The antibodies created at Bioventix are generated in sheep and 
are of particular benefit where the target is present at low concentration and 
where conventional monoclonal or polyclonal antibodies have failed to produce a 
suitable reagent. Bioventix currently offers a portfolio of antibodies to 
customers for both commercial use and R&D purposes, for the diagnosis or 
monitoring of a broad range of conditions, including heart disease, cancer, 
fertility, thyroid function and drug abuse. Bioventix currently supplies 
antibody products and services to the majority of multinational clinical 
diagnostics companies. Bioventix is based in Farnham, UK and its shares are 
traded on AIM under the symbol BVXP. 
 
 
 
END

(END) Dow Jones Newswires

November 08, 2022 11:08 ET (16:08 GMT)

Bioventix (AQSE:BVXP.GB)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024